FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Immunomedics Inc
Immunomedics Inc_20100114
Immunomedics Inc_20100121

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Immunomedics Inc patents


      
Recent patent applications related to Immunomedics Inc. Immunomedics Inc is listed as an Agent/Assignee. Note: Immunomedics Inc may have other listings under different names/spellings. We're not affiliated with Immunomedics Inc, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics Inc-related inventors


Search recent Press Releases: Immunomedics Inc-related press releases
Count Application # Date Immunomedics Inc patents (updated weekly) - BOOKMARK this page
12015008648203/26/15 new patent  Dye conjugated peptides for fluorescent imaging
22015005743202/26/15Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
32015003868602/05/15Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
42015001851601/15/15Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
52014037717312/25/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
62014037717712/25/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
72014037728712/25/14Anti-trop-2 antibody-drug conjugates and uses thereof
82014036992712/18/14Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
92014028686009/25/14Immunoconjugates with an intracellularly-cleavable linkage
102014028686109/25/14Rs7 antibodies
112014023420908/21/14Chimeric and humanized anti-histone antibodies
122014022717808/14/14Humanized anti-hla-dr antibodies
132014022717908/14/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
142014022718008/14/14Antibody-sn-38 immunoconjugates with a cl2a linker
152014022854108/14/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
162014021991408/07/14Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
172014021995608/07/14Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
182014021242507/31/14Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
192014019335907/10/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
202014017829406/26/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
212014017006506/19/14Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
222014015427306/05/14Anthracycline-antibody conjugates for cancer therapy
232014014738205/29/14Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
242014014092405/22/14Humanized l243 antibodies
252014012003505/01/14Rs7 antibodies
262014011286404/24/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
272014011286504/24/14Anti-cd19 antibodies
282014010581904/17/14In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
292014009925804/10/14Camptothecin-binding moiety conjugates
302014008683003/27/14Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
312014008683203/27/14Delivery system for cytotoxic drugs by bispecific antibody pretargeting
322014007962903/20/14Class i anti-cea antibodies and uses thereof
332014005806702/27/14Immunoconjugates with an intracellularly-cleavable linkage
342014004463902/13/14Antibody therapy
352014004464002/13/14Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
362014003754302/06/14Anti-pancreatic cancer antibodies
372014003826102/06/14Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
382014003828402/06/14Mammalian cell lines for increasing longevity and protein yield from a cell culture
392014001716801/16/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
402014001719701/16/14Anti-cd19 antibodies
412014000407801/02/14Immunoconjugates with an intracellularly-cleavable linkage
422013031582111/28/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
432013030917711/21/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
442013021656108/22/13Immunoconjugates with an intracellularly-cleavable linkage
452013020935608/15/13Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
462013021104408/15/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
472013017749807/11/13Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
482013017752607/11/13Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
492013017106407/04/13Anti-cd74 immunoconjugates and methods of use
502013017106507/04/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
512013017117607/04/13Anthracycline-antibody conjugates for cancer therapy
522013016421406/27/13Antibody-based depletion of antigen-presenting cells and dendritic cells
532013016478306/27/13Mammalian cell lines for increasing longevity and protein yield from a cell culture
542013015669106/20/13Antibody therapy
552013014278706/06/13Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
562013014329606/06/13Delivery system for cytotoxic drugs by bispecific antibody pretargeting
572013012191305/16/13Anti-cd19 antibodies
582013012347305/16/13Bispecific antibody targeting a complement factor or complement regulatory protein
592013009503404/18/13Anti-cd74 immunoconjugates and methods
602013009045804/11/13Immunoconjugates with an intracellularly-cleavable linkage
612013007818203/28/13Structural variants of antibodies for improved therapeutic characteristics
622013007826303/28/13Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
632013007132003/21/13Immunotherapy of autoimmune disorders using antibodies which target b-cells
642013007140603/21/13Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
652013007265903/21/13Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
662013003986102/14/13Dye conjugated peptides for fluorescent imaging
672013003449202/07/13Class i anti-cea antibodies and uses thereof
682012032856412/27/12Camptothecin-binding moiety conjugates
692012032863412/27/12Immunoconjugates with an intracellularly-cleavable linkage
702012032155312/20/12Ultrafiltration concentration of allotype selected antibodies for small-volume administration
712012028217811/08/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
722012027610011/01/12Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
732012023095309/13/12Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
742012021496908/23/12Methods and compositions for f-18 labeling of proteins, peptides and other molecules
752012019632608/02/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
762012018954207/26/12Anti-cd19 antibodies
772012018347207/19/12Immunotherapy of b-cell malignancies using anti-cd22 antibodies
782012018355007/19/12Therapeutic using a bispecific antibody
792012014908506/14/12Fusion proteins containing recombinant cytotoxic rnases
802012014137206/07/12Rs7 antibodies
812012014137506/07/12Anti-mucin antibodies for early detection and treatment of pancreatic cancer
822012013492005/31/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
832012011455605/10/12Immunotherapy of autoimmune disorders using antibodies which target b-cells
842012010723505/03/12Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
852012008829904/12/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
862012008261704/05/12Immunoconjugates with an intracellularly-cleavable linkage
872012007672703/29/12In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
882012006399303/15/12Therapeutic and diagnostic conjugates for use with multispecific antibodies
892012003979702/16/12Antibody therapy
902012004043102/16/12Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
912012003418502/09/12Anti-cd20 antibodies and fusion proteins therof and methods of use
922011031153112/22/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
932011030563112/15/11Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
942011030006612/08/11Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
952011029351312/01/11Immunoconjugates with an intracellularly-cleavable linkage
962011028691811/24/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
972011028080111/17/11Methods and compositions for f-18 labeling of proteins, peptides and other molecules
982011027470411/10/11Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
992011025605310/20/11Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
1002011024384110/06/11Antibody-based depletion of antigen-presenting cells and dendritic cells
1012011024454610/06/11Internalizing anti-cd74 antibodies and methods of use
1022011023630409/29/11Structural variants of antibodies for improved therapeutic characteristics
1032011023640409/29/11Methods for protein expression in mammalian cells in serum-free medium
1042011022940709/22/11Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1052011022364509/15/11Multivalent carriers of bi-specific antibodies
1062011019502308/11/11Internalizing anti-cd74 antibodies and methods of use
1072011018908508/04/11Antibody therapy
1082011018926808/04/11Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1092011017112607/14/11Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
1102011016507207/07/11Detection of early-stage pancreatic adenocarcinoma
1112011016507307/07/11Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1122011011701005/19/11Methods and compositions for administering therapeutic and diagnostic agents
1132011011710505/19/11Method of treating immune disease using b-cell antibodies
1142011011085405/12/11Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1152011007623303/31/11Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1162011007015503/24/11Anti-cd74 immunoconjugates and methods
1172011007015603/24/11Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
1182011006465303/17/11Class i anti-cea antibodies and uses thereof
1192011005248903/03/11Anti-cd19 antibodies
1202010031116212/09/10Mammalian cell lines for increasing longevity and protein yield from a cell culture
1212010028490611/11/10Internalizing anti-cd74 antibodies and methods of use
1222010027263610/28/10Anti-cd74 immunoconjugates and methods of use
1232010026649610/21/10Anti-cd74 immunoconjugates and methods of use
1242010026649710/21/10Internalizing anti-cd74 antibodies and methods of use
1252010023377909/16/10Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1262010022688409/09/10Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
1272010022117509/02/10Antibody therapy
1282010022117709/02/10Rs7 antibodies
1292010021666208/26/10Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1302010020296108/12/10D-amino acid peptides
1312010019626608/05/10Humanized anti-hla-dr antibodies
1322010019626708/05/10Humanized l243 antibodies
1332010019698908/05/10Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1342010018964107/29/10Novel strategies for improved cancer vaccines
1352010015880206/24/10Chimeric, human and humanized anti-csap monoclonal antibodies
1362010015880306/24/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1372010013662606/03/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1382010010458904/29/10Immunoconjugates with an intracellularly-cleavable linkage
1392010007484003/25/10Anthracycline-antibody conjugates for cancer therapy
1402010006813603/18/10Anti-cd19 antibodies
1412010004054102/18/10Structural variants of antibodies for improved therapeutic characteristics
1422010003473802/11/10Structural variants of antibodies for improved therapeutic characteristics
1432010001504601/21/10Camptothecin-binding moiety conjugates
1442010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1452010000885501/14/10Production and use of novel peptide-based agents with bispecific antibodies
1462010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1472009030458012/10/09Anti-pancreatic cancer antibodies
1482009029903312/03/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1492009029109311/26/09Immunoconjugates with an intracellularly-cleavable linkage
1502009028575211/19/09Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
1512009027464911/05/09Bispecific antibody point mutations for enhancing rate of clearance
1522009025273110/08/09Multivalent carriers of bi-specific antibodies
1532009025317910/08/09Mammalian cell lines for increasing longevity and protein yield from a cell culture
1542009024613010/01/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1552009024613110/01/09Production and use of novel peptide-based agents for use with bi-specific antibodies
1562009024621410/01/09Fusion proteins containing recombinant cytotoxic rnases
1572009023875709/24/09Methods and compositions for administering therapeutic and diagnostic agents
1582009024003709/24/09Humanized antibodies and methods of humanizing antibodies
1592009018597407/23/09Chimeric, human and humanized anti-granulocyte antibodies and methods of use
1602009015516606/18/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1612009015525306/18/09Anti-cd20 antibodies and fusion proteins therof and methods of use
1622009011114304/30/09Methods and compositions for mammalian cell lines for transfection and protein expression in serum-free medium
1632009009259804/09/09Antibody therapy
1642010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1652010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE